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Abstract
Though aspirin is a well-established antiplatelet agent, the mechanisms of aspirin resistance 
remain poorly understood. Metabolomics allows for measurement of hundreds of small molecules 
in biological samples enabling detailed mapping of pathways involved in drug response. We 
defined the metabolic signature of aspirin exposure in subjects from the Heredity and Phenotype 
Intervention (HAPI) Heart Study. Many metabolites, including known aspirin catabolites, changed 
upon exposure to aspirin and pathway enrichment analysis identified purine metabolism as 
significantly affected by drug exposure. Further, purines were associated with aspirin response and 
poor responders had higher post-aspirin adenosine and inosine than good responders 
(N=76;p<4×10-3 both). Using our established “pharmacometabolomics-informs-
pharmacogenomics” approach we identified genetic variants in adenosine kinase (ADK) 
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associated with aspirin response. Combining metabolomics and genomics allowed for more 
comprehensive interrogation of mechanisms of variation in aspirin response - an important step 
toward personalized treatment approaches for cardiovascular disease.
Introduction
Aspirin is one of the most commonly used medications worldwide and, as an antiplatelet 
agent, is employed for both primary prevention of cardiovascular disease (CVD) and 
secondary prevention of recurrent cardiovascular events following a myocardial infarction.
(1) Aspirin’s antiplatelet actions can significantly reduce the risk of cardiovascular death, 
but atherothrombotic events (i.e. clinical aspirin resistance) are relatively common and 
~25% of high risk patients show persistent platelet reactivity (i.e. laboratory aspirin 
resistance) while on aspirin therapy.(2, 3)
Though well documented, the mechanisms underlying aspirin resistance are not completely 
understood. Heritability estimates suggest a genetic component to aspirin resistance(4), but 
few genetic variants have been identified.(5) Aspirin acts by irreversibly inhibiting 
cyclooxygenase-1(COX1) and blocking conversion of arachidonic acid to the potent platelet 
agonist thromboxane A2.(6) Incomplete inhibition of COX1 by aspirin has been observed in 
several settings, however poor response despite complete inhibition of COX1 has also been 
reported.(3, 7) Identification of novel pathways involved in aspirin resistance could help 
clarify this mechanism.
Genomic and, more recently, metabolomic approaches have both been employed separately 
in the study of CVD predictors and treatment outcomes. Early successes in the CVD arena 
include discovery of the CYP2C19*2 variant in clopidogrel response, identification of citric 
acid cycle metabolites that may be useful in diagnosis of myocardial ischemia, and the 
association between branched-chain amino acids and dietary lipid phosphatidylcholine with 
coronary artery disease.(8-10) Further, we have used a variety of metabolomics tools to map 
global effects of drugs on metabolism and to map pathways linked to variation in response.
(11-14) While these pharmacometabolomic studies have been successful in their own right, 
there has been additional success when this technology is harnessed to robust genomic 
methodologies using an approach coined pharmacometabolomic-informed-
pharmacogenomics.(15-17)
With this in mind, we have employed both of these complimentary technologies to 
investigate novel mechanisms of aspirin resistance. We first conducted metabolomic 
profiling of serum samples from healthy subjects before and after low-dose aspirin therapy 
to characterize the metabolomic signature of aspirin exposure and identify important 
pathways affected. We extended these findings by investigating the differences in 
metabolomic profiles between good and poor responders on aspirin. Finally, we used 
information from metabolomic profiling to conduct focused genetic association analyses 
using this pharmacometabolomic-informed-pharmacogenomics approach.
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Results
Participant Characteristics
In the current analysis, samples from 76 healthy volunteers who underwent a two-week 
aspirin intervention as part of the Heredity and Phenotype Intervention (HAPI) Heart Study 
were selected for metabolomic profiling.(18) Participant characteristics are provided in 
Table 1. Specifically, pre- and post-aspirin serum samples were profiled for 40 good 
responders and 36 poor responders (as measured by change in collagen-stimulated ex vivo 
platelet aggregation), using an untargeted gas-chromatography (GC)-MS-based 
metabolomics platform. As designed, aspirin intervention lowered collagen stimulated 
platelet aggregation in good but not poor responders (p<1×10-3). Collagen stimulated 
aggregation was slightly higher in poor vs. good responders pre-aspirin (p=0.02) and 
significantly higher in poor responders post-aspirin (p<1×10-3). Arachidonic acid stimulated 
aggregation was slightly higher in poor responders both pre- and post-aspirin intervention 
(p<0.02 both) but there was no difference in change in aggregation between the groups 
(p=0.97). Samples were selected to be approximately half men and half women in each 
group. No difference between good and poor responders was observed for age or body mass 
index.
Changes in Metabolite Levels Post-Aspirin Intervention
Multi-level principal component analysis (ML-PCA) was used to investigate the largest 
sources of variation in serum metabolic profiles of all participants, using the 180 known 
metabolites measured by GC-MS. While the first two principal components did not 
distinguish between samples groups, pre- and post-aspirin samples were separated by the 
third principal component (see Supplemental Information). Using linear mixed models to 
analyze individual metabolites we found eighteen metabolites significantly altered by aspirin 
intervention in all 76 participants (Table 2). The two metabolites with the largest magnitude 
of change were known aspirin catabolites - salicylic acid and salicyluric acid. To identify 
novel pathways implicated in aspirin exposure, pathway enrichment analysis was performed 
using the other sixteen metabolites. Interestingly, we observed that the “Purine Metabolism” 
pathway was significantly affected by aspirin exposure (p=0.003), with significant changes 
for six metabolites involved in this pathway. Specifically, adenosine 5’-phosphate (AMP), 
inosine, guanosine and adenosine levels were increased (p≤0.004 for all) in post-aspirin 
compared to pre-aspirin samples. In contrast, hypoxanthine and xanthine levels were 
decreased (p<1×10-3 for both) post-aspirin. Uric acid, the end product of this pathway, was 
not significantly associated with aspirin exposure.
Post hoc power calculations were completed and showed that we had 89% power to identify 
differences between pre- and post-aspirin samples assuming a standard deviation of 0.75 and 
difference of 0.28 (which we observed for AMP).
Purine Metabolite Differences Between Good and Poor Responders
Based on our pathway enrichment analysis, we next evaluated whether purine metabolites 
were differentially affected by aspirin intervention in good vs. poor responders. We 
employed the same linear mixed models approach separately in the 2 response groups for 7 
Yerges-Armstrong et al. Page 3
Clin Pharmacol Ther. Author manuscript; available in PMC 2014 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
purine metabolites successfully measured by GC-MS: AMP, adenosine, inosine, guanosine, 
xanthine, hypoxanthine and uric acid. We also evaluated differences in purine metabolite 
levels of good vs. poor responders both pre- and post-aspirin intervention. Results of these 
analyses are depicted in Figure 1. Although inosine levels were significantly higher post-
aspirin in both good and poor responders (p=<2×10-3 both), the post-aspirin level of inosine 
was significantly higher in the poor compared to good responders (p=0.003). Adenosine was 
increased in poor responders upon aspirin exposure (p=4×10-3), and post-aspirin levels were 
also significantly higher in poor responders compared to good responders (p=0.02). 
Metabolites located in other branches (guanosine) or downstream from the pathway 
(hypoxanthine and xanthine) were significantly affected by aspirin exposure, but changes 
were similar in both response groups. Since sex differences in aspirin response are well 
established(19) we included sex as a covariate in all analyses and also tested for association 
with pre- and post-aspirin purine metabolite levels. While sex was associated with both pre- 
and post-intervention inosine and uric acid levels, we did not detect a significant interaction 
between sex and aspirin response for any purine metabolites.
Replication of Purine Metabolite Findings
Inosine, guanosine, hypoxanthine, xanthine and uric acid were successfully measured in a 
replication group of N=37 additional subjects from the HAPI study who were either good 
(N=19) or poor responders (N=18). As in the original sample, we observed higher levels of 
inosine (p<10-3) and lower levels of hypoxanthine (p=0.005) in post-aspirin vs. pre-aspirin 
samples. Further we observed significant differences in inosine levels between good and 
poor responders to aspirin therapy (see Supplemental Information). Specifically, inosine 
levels were higher in poor responders both pre and post-aspirin intervention (p=0.005 and 
p=0.05 respectively). Adenosine and AMP were unable to be measured in this replication 
sample.
Genetic Association of Purine Related Genes and Platelet Aggregation
Since the pharmacometabolomic findings implicated the purine metabolism pathway in 
aspirin response, we used our “Pharmacometabolomics-Informs-Pharmacogenomics” 
approach to identify candidate genes. Specifically, we selected nine genes directly involved 
in biosynthesis, degradation or transport of purine metabolites (Table 3), and conducted 
association analyses between single nucleotide polymorphisms (SNPs) in these gene regions 
and ex vivo platelet aggregation. We used data from 718 HAPI study participants who 
underwent aspirin intervention. 1,035 SNPs in the nine gene regions had high-quality 
imputation scores (r2>0.3), were observed at an appreciable frequency (>5% minor allele 
frequency), and were used for subsequent analyses.
Using a false discovery rate (FDR) cut-off of α=0.01, we identified 51 SNPs in the 
adenosine kinase (ADK) gene region that were associated with change in platelet 
aggregation during aspirin therapy (p<5×10-4). The most strongly associated SNP in this 
region is the intronic variant rs16931294. The less common G allele was associated with 
higher platelet aggregation post-aspirin than the more common A allele (β=0.8; 
p.=3.4×10-4), so on average, individuals with the GG genotype had ~1.6Ω higher post-
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aspirin platelet aggregation than individuals with the AA genotype after accounting for age, 
sex and pre-aspirin aggregation value.
We next utilized data from 341 subjects from the Pharmacogenomics of Antiplatelet 
Intervention (PAPI) study to replicate this finding. The PAPI study measured platelet 
aggregation at three time points, before any antiplatelet intervention, after a one-week 
intervention with clopidogrel, another widely used antiplatelet agent targeting a platelet 
ADP receptor, and after addition of one, 81mg dose of aspirin to the clopidogrel regimen. 
We tested rs16931294 for association with post-aspirin+clopidogrel ex vivo platelet 
aggregation while adjusting for age, sex and clopidogrel only aggregation and again 
observed that the G allele was associated with higher platelet aggregation (β=1.9; p=0.002).
Association of rs16931294 with Metabolite Levels
We conducted exploratory analyses to determine whether rs16931294 in ADK was 
associated with pre- and post-aspirin purine pathway metabolites. These exploratory 
analyses were carried out in 74 participants who had available metabolomic and genomic 
data. Despite the small sample size, the G allele of rs16931294 was significantly associated 
with higher pre-aspirin levels of AMP (p=0.04), xanthine (p=0.01) and hypoxanthine 
(p=0.02) compared to the A allele. Post-aspirin levels of inosine (p=0.007) and guanosine 
(p=0.02) are also higher for the G compared to the A allele (Figure 2).
Ratios of Metabolites to AMP
Since ADK is involved in the conversion of adenosine to AMP, we assessed the ratios of 
other purine metabolites to AMP in good and poor responders. We observed significantly 
higher levels of the adenosine-to-AMP (p=0.008) and the inosine-to-AMP (p=0.005) ratios 
in the poor responders as compared to good responders after aspirin exposure (see 
Supplemental Information). We also observed significant associations between rs16931294 
genotype and the inosine-to-AMP ratio (p=0.002) and guanosine-to-AMP ratio (p=0.02) 
after aspirin intervention as well as uric acid-to-AMP ratio before aspirin (p=0.05; see 
Supplemental Information).
Discussion
In this study, we investigated the metabolic signature of aspirin exposure in healthy 
volunteers using untargeted GC-MS metabolomic profiling. We first observed that aspirin 
significantly affected metabolites involved in purine catabolism in the overall population. 
Further analysis showed differential changes in purine metabolites in good compared to poor 
responders which was replicated in an independent sample and informed our 
pharmacogenomic investigation. Our data provide compelling evidence of the importance of 
purine metabolism in aspirin’s mechanism of action and variation in response.
As part of the general metabolic signature of aspirin exposure, we observed significantly 
higher concentrations of inosine and adenosine after aspirin in accordance with previous 
studies that demonstrated both of these as inhibitors of platelet aggregation. Adenosine 
activates the adenosine A2 receptor on the surface of platelets, which in turn stimulates 
adenylate cyclase, increases cAMP levels, and lowers intracellular calcium concentration 
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thereby reducing platelet aggregation.(20) Adenosine reduces recurrent thrombosis, alters 
blood flow after coronary hypoperfusion, and improves arterial patency.(21) Inosine has 
been shown to inhibit platelet aggregation, lower intracellular calcium concentration, and 
reduce collagen-induced thromboxane A2 formation.(22) Further, Hsiao et al. reported that 
inosine substantially attenuates middle cerebral artery occlusion-induced focal cerebral 
ischemia with a 34% reduction in infarct size in inosine-treated rats compared to controls, 
suggesting that inosine may help improve outcomes following ischemia-reperfusion brain 
injury or other thromboembolic diseases.(22)
The observation of higher post-aspirin levels of adenosine and inosine in poor-responders 
compared to good-responders is not completely understood. Thrombosis is a tightly 
regulated process, and we do not know if the increased concentration of adenosine and 
inosine is a cause or consequence of the poor response to aspirin. While further functional 
work is needed, we posit three mechanisms that may be responsible for these observations. 
First, extracellular adenosine levels mainly stem from phospho-hydrolysis of precursor 
nucleotides such as ATP, ADP and AMP(23), and we speculate that our results reflect 
higher levels of one or more of these metabolites. ADP is a well-described pro-aggregant 
molecule and previous publications have already described aspirin resistance related to 
increased sensitivity of platelets to ADP.(24) Second rapid adenosine transport is the major 
regular for adenosine in plasma(23), and we could also speculate that higher serum levels 
may be indicative of poor uptake by platelets or other cells. Finally, differences in 
intracellular purine metabolism by enzymes such as ADK could contribute to the observed 
difference between good and poor responders.
We also observed a significant increase in guanosine levels in both good- and poor-
responders after aspirin. The effect of guanosine on platelet function is unclear, but the role 
of downstream derivatives of guanosine on platelet function is well-established. One 
derivative, cGMP, plays a critical role in platelet aggregation and regulating vascular 
function. Abnormal cGMP signalling or production can result in coronary artery disease, 
atherosclerosis, and hypertension.(25) Guanosine is also believed to regulate extracellular 
adenosine by inhibiting adenosine disposition into several types of human cells(26) which 
could further influence aggregation.
Hypoxanthine and xanthine decreased in both good- and poor-responders after aspirin 
intervention. Hypoxanthine is converted directly into xanthine via xanthine oxidase, and 
prior investigations have shown that the interaction between xanthine and xanthine oxidase 
produces reactive oxygen species (e.g. superoxide), which results in activation, aggregation, 
and release reaction of platelets.(27, 28) Given these data, we speculate whether aspirin 
leads to decreased hypoxanthine and xanthine levels thereby minimizing reactive oxygen 
species generation and inhibiting the pro-thrombotic effect they have on platelets. Xanthine 
oxidase also metabolizes xanthine into uric acid, a potent risk factor for CVD, but we did 
not observe differences in uric acid levels after aspirin unlike previous reports.(29, 30)
Our study illustrates the power of untargeted metabolic profiling to identify new metabolic 
pathways implicated in a drug’s mechanism of action; in this case, the purine metabolic 
pathway in aspirin exposure. While individual purines have been previously implicated in 
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platelet biology, this untargeted approach allowed us to quickly hone in on the purine 
pathway, inform our genomic inquiries and generate repeatable results. A limitation of such 
untargeted approaches is that several metabolites from the pathway (e.g. ADP) were not 
measured, furthermore, we were unable to measure AMP and adenosine in our replication 
sample. Based on these findings, we believe a more comprehensive assessment of purine 
metabolites in a larger sample is warranted and could shed further light on the mechanism of 
purine metabolism in aspirin response. The current analysis was performed in healthy 
volunteers, which is advantageous in that it minimizes confounding, but additional studies in 
coronary artery disease patients are needed to assess clinical outcomes.
These pharmacometabolomic findings informed our pharmacogenomic investigation where 
we identified variants in ADK associated with both aspirin response and purine metabolite 
levels. The ADK enzyme catalyses the formation of adenosine to AMP by transferring the 
gamma-phosphate of ATP to adenosine and is an important regulator of extracellular 
adenosine.(31) We identified several associated SNPs in this attractive candidate gene 
including the intronic variant rs16931294. The G allele of this variant was associated with 
poor response to aspirin and higher post-aspirin inosine levels which is consistent with our 
observation that higher post-aspirin inosine is associated with poor aspirin response. Despite 
being on concurrent clopidogrel therapy, we were able to replicate the genetic association 
between ADK variants and platelet aggregation measures in the PAPI study. No association 
between genotype and adenosine-to-AMP ratio was detected, but we did observe significant 
associations with inosine-to-AMP and guanosine-to-AMP ratios. Adenosine is quickly 
removed from the blood into red blood cells and our results may not reflect intracellular 
metabolite levels which may explain the lack of association.(32) ADK is a notably large 
gene with expansive blocks of linkage disequilibrium so our most associated variant 
rs16931294 is unlikely the causal mutation. Further genetic association studies with diverse 
populations would be advantageous for identifying likely causal variants so functional 
studies could be performed.
While pharmacogenomics alone has identified genetic variants of large effect size for other 
drugs, there has been limited success during the genome-wide association era identifying 
underlying genetic variation to aspirin response despite its common use in medicine. This 
may be due to the complex mechanism in which aspirin works and more targeted 
approaches to gene discovery may be warranted. Our pharmacometabolomics investigation 
not only identified novel metabolic pathways on its own but also successfully informed our 
pharmacogenomic investigation. The present investigation illustrates that the combined use 
of pharmacometabolomics and pharmacogenomics represents a promising approach to 
understanding mechanisms of resistance in anti-platelet therapy and toward individualizing 
aspirin therapy.
Methods
Study design and population
The HAPI Heart Study was initiated in 2003 to measure cardiovascular response to short-
term interventions and identify the genetic and environmental determinants of these 
responses.(18) Participants were members of the Old Order Amish population from 
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Lancaster County, PA, at least 20 years of age and relatively healthy. As part of the HAPI 
study, 745 participants participated in a short-term aspirin intervention(19) of one 81mg 
aspirin/day for 14 consecutive days. Ex vivo platelet aggregometry was performed prior to 
aspirin therapy and again the morning after the last dose. Intervention compliance was high 
and monitored by medication inventory. Details on sample collection and ex vivo platelet 
testing are provided in the supplement.
In the present metabolomics study, samples originated from 76 HAPI participants. 
Participants were grouped into sex-specific quartiles of aspirin response measured by post-
aspirin collagen-stimulated (2μg/mL) platelet aggregation adjusted for participant age and 
pre-aspirin, collagen-stimulated platelet aggregation. Non-first-degree relatives from the 1st 
(good responders) and the 4th (poor responders) sex-specific drug-response quartiles were 
selected for metabolic profiling. Samples from 39 women (20 good responders, 19 poor 
responders) and 37 men (20 good responders, 17 poor responders) were used in the current 
analysis. Metabolomic profiling in a replication set of 49 HAPI participants (19 good and 20 
poor responders) was performed to validate findings.
All study procedures were in accordance with the Declaration of Helsinki. The study was 
approved by the Institutional Review Board of the University of Maryland, Baltimore, and 
other participating institutions and was monitored by an external Data Safety and 
Monitoring Board. Participants provided informed consent, including permission to contact 
relatives, before participation.
Metabolite Measurement by GC-MS
Fifteen μl aliquots were extracted by 1μl of degassed acetonitrile:isopropanol:water (3:3:2) 
at −20°C, centrifuged and decanted with subsequent evaporation of the solvent to complete 
dryness. A clean-up step with acetonitrile/water (1:1) removed membrane lipids and 
triglycerides and the supernatant was dried down again. Internal standards C8-C30 FAMEs 
were added and the sample was derivatized with methoxyamine hydrochloride in pyridine 
and subsequently by MSTFA (Sigma-Aldrich) for trimethylsilylation of acidic protons.
A Gerstel MPS2 automatic liner exchange system was used to inject 1 ml of sample at 50°C 
(ramped to 250°C) in splitless mode with a 25-second splitless time. An Agilent 6890 gas 
chromatograph (Santa Clara, CA) was used with a 30m long, 0.25mm i.d. Rtx5Sil-MS 
column with 0.25μm 5% diphenyl film; an additional 10m integrated guard column was 
used (Restek, Bellefonte PA). Chromatography was performed at a constant flow of 1 ml/
minute, ramping the oven temperature from 50°C to 330°C over 22 minutes. MS used a 
Leco Pegasus IV time of flight (TOF)-MS with 280°C transfer line temperature, electron 
ionization at -70V and an ion source temperature of 250°C. Mass spectra were acquired 
from m/z 85-500 at 20 spectra/second and 1750 V detector voltage. Result files were 
exported to our servers and further processed by our metabolomics BinBase database(33). 
All database entry in BinBase(34) were matched against the Fiehn mass spectral library of 
1,200 authentic metabolite spectra using retention index and mass spectrum information or 
the NIST05 commercial library.
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Statistical Analysis
Additional analysis methods including pathway enrichment analysis, multi-level PCA and 
replication analyses in PAPI are provided in the supplemental.
Metabolomics data analysis—Missing ion intensity values were assumed to result from 
areas falling below detection limits and were imputed with the observed minimum for that 
metabolite divided by 2. To improve normality, metabolite response values were log-
transformed before statistical investigation. The metabolite response values obtained with 
the GC-MS platform do not represent real concentrations and cannot be used for making 
quantitative comparisons between metabolites. To improve readability, we report 
standardized metabolite values which are metabolite values divided by the mean metabolite 
value for this in all study samples in all tables and figures.
Linear mixed models (LMM)—Significance of the effects of aspirin and phenotype on 
metabolite level was assessed by linear modeling and linear mixed modeling in GenStat 14th 
edition (VSN International, Hemel Hempstead, UK, www.GenStat.co.uk).
The first global LMM included all data for each metabolite:
(1)
in which i=1,2…81, yi,t=vector of metabolite concentrations for the ith individual at time t; 
t=time (before/after aspirin); gender=men or women; phenotype=good or poor responder; 
α0…α6=regression coefficients; δi= random effect associated with the ith individual; 
εi,t=error term.
The second linear model included data before aspirin:
(2)
The third linear model included data after aspirin:
(3)
Model (1) was fitted for each 180 metabolites and the effect of aspirin on metabolite level 
was considered significant when p<0.05 for α1. False Discovery Rate (FDR) with a 
significance threshold q<0.1 was used to address multiple comparisons.
All three models were fitted for each purine metabolite and purine metabolite ratios. Model 
(1) was fitted again, without the “phenotype” effect, using the population of good (or poor) 
responders only, and the main effect of aspirin exposure was investigated as previously. 
Models (2) and (3) were fitted to investigate the effect of phenotype, which was considered 
significant pre- and post-aspirin when p<0.05 for β2 or γ2 respectively.
Genetic analyses—The HAPI Heart Study has extensive, existing genotyping data, 
including genome-wide association genotyping and genotype imputation. Detailed genetic 
analysis methods are provided in the supplementary material but in brief:
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We conducted genetic association analyses of ex vivo platelet aggregation in HAPI (n=718) 
with SNPs falling in candidate gene regions identified by metabolomics analyses. We 
defined candidate gene regions as the full transcript +/-30kb to include proximal regulatory 
regions. The association with ex vivo platelet aggregation was replicated in the PAPI study 
for the most strongly associated SNP, rs16931294. We also conducted association analysis 
between rs16931294 and relevant purine metabolite levels. All analyses account for age, 
sex, pre-aspirin platelet aggregation and family structure.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Study Highlights
What is the current knowledge on the topic?
Mechanisms of aspirin resistance are not well established. Additional studies may 
provide insights about mechanisms of clinical resistance to aspirin and approaches to 
modify therapy for patients who are resistant and have poor clinical outcomes.
What question did this study address?
The current study sought to use pharmacometabolomic and pharmacogenomic 
approaches to identify potential mechanisms of aspirin resistance and to map implicated 
pathways.
What this study adds to our knowledge?
This study identified purine metabolites including inosine and adenosine that are 
associated with variation in aspirin response. Further, variants in the adenosine kinase 
(ADK) gene were associated with levels of ex vivo platelet aggregation.
How this might change clinical pharmacology and therapeutics?
In addition to identifying the potential importance of purine metabolism in aspirin 
response, this study highlights the power of combining metabolomics and genomic 
approaches to more comprehensively interrogate the biological mechanisms of drug 
response – a step towards more personalized approaches to therapy.
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Figure 1. 
Data represents standardized mean and standard error of metabolite levels before (blue) and 
after (red) aspirin therapy in good vs. poor responders. Metabolites in bold were measured in 
this study. #:p<0.05 for testing the difference in metabolite levels after vs. before aspirin. 
*:p<0.05 for testing the difference in metabolite levels in good vs. poor responders. Key: 
ATP, ADP and AMP: adenosine tri-, di- and mono-phosphate, AMPS: adenylosuccinate, 
IMP: inosine monophosphate, XMP: xanthosine monophosphate, GTP, GDP, GMP: 
guanosine tri-, di- and monophosphate, ADK: adenosine kinase.
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Figure 2. 
Levels of purine metabolites are presented by genotype for pre-aspirin (blue) and post-
aspirin (red) samples. * indicates significant additive association analysis (p<0.05). 
Genotype specific samples sizes are AA=43, AG=29, GG=2. Uric Acid was not significant 
by genotype group for either pre- or post-aspirin measures (see Supplemental Information).
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Table 1
Participant Characteristics
Good responders (N=40) Poor responders (N=36) p-value
Demographics
 Gender* (%Men [N]) 50% [20] 47% [17] 0.81
 Age (year) 44.0±14.4 42.8±12.2 0.69
 BMI (kg/m2) 26.5±4.4 26.2±4.3 0.78
Platelet aggregation, collagen 2 μg/mL
 Before aspirin (Ω) 13.3±1.9 14.2±1.9 0.05
 After aspirin (Ω) 5.7±1.9 14.2±1.9 <0.0001
 Change* (Ω) -7.6 ±2.1 0.03±2.3 <0.0001
Platelet aggregation, arachidonic acid
 Before aspirin (Ω) 9.4±2.8 11.0±3.0 0.02
 After aspirin (Ω) 0.4±1.3 2.0±3.5 0.01
 Change (Ω) -9.0 ±3.2 -9.1±4.4 0.97
*Samples were categorized as good and poor responders based on change in collagen stimulated ex vivo platelet aggregation and selected to have 
approximately equal numbers of men and women in each category.
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Table 3
Purine Pathway Candidate Genes
Gene
Role Name Symbol Function
Synthesis & salvage AMP 5’ nucleotidase NT5C1A Converts AMP to adenosine
Adenosine deaminase ADA Converts adenosine to inosine
Adenosine kinase ADK Converts adenosine to AMP
AMP deaminase 1 AMPD1 Converts AMP to IMP
AMP deaminase 2 AMPD2 Converts AMP to IMP
AMP deaminase 3 AMPD3 Converts AMP to IMP
Transport ATP-binding cassette C4 ABCC4 Transports adenine nucleotides inside platelets and into dense granules
Degradation Purine nucleoside phosphorylase PNP Converts inosine to hypoxanthine
Xanthine oxidase XDH Converts hypoxanthine to xanthine
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